Residual and Recurrent Gastrointestinal Stromal Tumors With KIT Mutations: Findings at First Follow-Up CT After Imatinib Treatment

被引：3

作者：

Choi, Dongil ^{[1
,2
]}

Yoo, Eun Young ^{[1
,2
]}

Kim, Kyoung-Mee ^{[3
]}

Sohn, Tae Sung ^{[4
]}

Lee, Won Jae ^{[1
,2
]}

Lee, Ji Young ^{[1
,2
]}

Chang, Ilsoo ^{[1
,2
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Dept Radiol, Kangnam Ku, Seoul 135710, South Korea

[2] Sungkyunkwan Univ, Sch Med, Ctr Imaging Sci, Kangnam Ku, Seoul 135710, South Korea

[3] Sungkyunkwan Univ, Sch Med, Dept Pathol, Samsung Med Ctr, Seoul, South Korea

[4] Sungkyunkwan Univ, Sch Med, Dept Surg, Samsung Med Ctr, Seoul, South Korea

来源：

AMERICAN JOURNAL OF ROENTGENOLOGY | 2009年 / 193卷 / 02期

关键词：

cystic change; follow-up CT; gastrointestinal stromal tumor; GIST; imatinib treatment; KIT mutation; POSITRON-EMISSION-TOMOGRAPHY; TYROSINE KINASE; POOR-PROGNOSIS; CYSTIC CHANGES; MESYLATE; INHIBITION; METASTASES; RESISTANCE; DELETIONS; BIOLOGY;

D O I：

10.2214/AJR.08.2106

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

OBJECTIVE. The purpose of this study was to correlate findings on the first follow-up CT after treatment with imatinib in patients with residual or recurrent gastrointestinal stromal tumors (GISTs) with the different types of KIT mutation present at initial resection. CONCLUSION. Residual and recurrent GISTs with KIT mutation of exon 11 deletion more frequently showed both tumor shrinkage and cystic change on 2-month follow-up CT images after the start of imatinib treatment than did other mutation types.

引用

页码：W100 / W105

页数：6

共 50 条

[1] Long-Term Follow-Up Outcome of Imatinib Mesylate Treatment for Recurrent and Unresectable Gastrointestinal Stromal Tumors
Saito, Seiko
Nakata, Katsunori
Kajiura, Shinya
Ando, Takamaso
Hosokawa, Ayumu
Sugiyama, Toshiro
DIGESTION, 2013, 87 (01) : 47 - 52
[2] Effect of KIT mutations on response to imatinib in gastrointestinal stromal tumors
Nature Clinical Practice Oncology, 2006, 3 (8): : 411 - 411
[3] KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance
Song Zheng
Ke-er Huang
Yue-long Pan
Yao Zhou
Song-dan Pan
Xin Li
Jing Jia
Xiao-liang Zheng
De-you Tao
Gastric Cancer, 2015, 18 : 796 - 802
[4] KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance
Zheng, Song
Huang, Ke-er
Pan, Yue-long
Zhou, Yao
Pan, Song-dan
Li, Xin
Jia, Jing
Zheng, Xiao-liang
Tao, De-you
GASTRIC CANCER, 2015, 18 (04) : 796 - 802
[5] Value of CT in the diagnosis and follow-up of gastrointestinal stromal tumors
Gong, Jing-Shan
Zuo, Min
Yang, Peng
Zang, Da
Zhang, Yue
Xia, Ligang
Xu, Jian-Min
Wang, Xiaomei
Yu, Xiaofang
CLINICAL IMAGING, 2008, 32 (03) : 172 - 177
[6] KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors
De Giorgi, Ugo
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1146 - 1147
[7] Follow up of three cases after adjuvant treatment of high risk gastrointestinal stromal tumors with Imatinib
Armbrust, T.
Sobotta, M.
Ramadori, G.
ANNALS OF ONCOLOGY, 2007, 18 (06) : 1123 - 1125
[8] KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors -: Reply
Heinrich, Michael C.
Corless, Christopher L.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1147 - 1148
[9] Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
Wardelmann, E
Merkelbach-Bruse, S
Pauls, K
Thomas, N
Schildhaus, HU
Heinicke, T
Speidel, N
Pietsch, T
Buettner, R
Pink, D
Reichardt, P
Hohenberger, P
CLINICAL CANCER RESEARCH, 2006, 12 (06) : 1743 - 1749
[10] Complete Remission of Recurrent Gastrointestinal Stromal Tumors After Treatment with Imatinib: Report of a Case
Michiya Kobayashi
Ken Okamoto
Hajime Nakatani
Takehiro Okabayashi
Tsutomu Namikawa
Kengo Ichikawa
Hiroyuki Kitagawa
Keijiro Araki
Surgery Today, 2006, 36 : 727 - 732

← 1 2 3 4 5 →